skip to Main Content
Dr. Tanios Bekaii-Saab

Disappointing Results of a Phase II Trial Using Angiogenesis Inhibitor

That’s the question researchers hoped to answer in a phase II double-blind trial comparing mFOLFIRINOX plus ramucirumab versus mFOLFIRINOX plus placebo in advanced pancreatic cancer patients. Results of the trial were presented at the 2021 ASCO GI Cancer Symposium. Ramucirumab is a monoclonal antibody that attaches to and inhibits a molecule called VEGFR-2, a vascular…

Back To Top